Oral Drug
Cocrystal Pharma Selects Two Lead Antiviral Drug Candidates for its COVID-19 Oral Drug Program
2022-01-30
Shanghai’s Everest Medicines Licenses COVID-19 Oral Antivirals from Singapore’s National Drug Discovery Platform
2022-01-17
Daiichi Sankyo to Launch mRNA COVID-19 Vaccine in 2022, Shionogi Presents Clinical Results of COVID-19 Oral Drug
2021-10-22
LATEST
ImmunityBio’s ANKTIVA® Granted FDA Approval: Breakthrough IL-15 Receptor Agonist First-in-Class for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
2024-04-24
Takeda, Astellas, and Sumitomo Mitsui Banking Declare Agreement For Early Drug Discovery Program Incubation in Joint Venture
2024-04-23
EVENT
2024-04-27
2024 Biomedical Final Pitch Competition
Room DA1620, Dana Building, Dana-Farber Cancer Institute, 99 Jimmy Fund Way, Boston, MA 02115